# An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

> **NCT02997176** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 38 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT02997176
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-02-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997176, "An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02997176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*